Study S000113

A Phase II, Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of HRS-4729 Injection in Participants With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT07843862
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 240
Start: 2026-10
Primary completion: 2027-04
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:HRS-4729 Injection; DRUG:Mazdutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change From Baseline in HbA1c [Baseline, Week 28]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.